431 related articles for article (PubMed ID: 32496160)
1. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
[TBL] [Abstract][Full Text] [Related]
2. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
3. PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
Wang AZ; O’Conno LP; Yerram NK; Long L; Zeng J; Mehralivand S; Harmon SA; Lebastchi AH; Ahdoot M; Gomella PT; Gurram S; Choyke PL; Merino MJ; Shih JH; Wood BJ; Turkbey B; Pinto PA
J Urol; 2020 Dec; 204(6):1229-1235. PubMed ID: 32716685
[TBL] [Abstract][Full Text] [Related]
4. Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?
Kim H; Pak S; Park KJ; Kim MH; Kim JK; Kim M; You D; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Clin Genitourin Cancer; 2020 Feb; 18(1):50-55. PubMed ID: 31640913
[TBL] [Abstract][Full Text] [Related]
5. The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy.
Williams C; Khondakar NR; Daneshvar MA; O'Connor LP; Gomella PT; Mehralivand S; Yerram NK; Egan J; Gurram S; Rompré-Brodeur A; Webster BR; Owens-Walton J; Parnes H; Merino MJ; Wood BJ; Choyke P; Turkbey B; Pinto PA
J Urol; 2021 Nov; 206(5):1157-1165. PubMed ID: 34181465
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
Raman AG; Sarma KV; Raman SS; Priester AM; Mirak SA; Riskin-Jones HH; Dhinagar N; Speier W; Felker E; Sisk AE; Lu D; Kinnaird A; Reiter RE; Marks LS; Arnold CW
J Urol; 2021 Sep; 206(3):595-603. PubMed ID: 33908801
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
8. Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology-Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?
Calio BP; Sidana A; Sugano D; Gaur S; Maruf M; Jain AL; Merino MJ; Choyke PL; Wood BJ; Pinto PA; Turkbey B
J Urol; 2018 Apr; 199(4):976-982. PubMed ID: 29154904
[TBL] [Abstract][Full Text] [Related]
9. Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?
Stonier T; Tin AL; Sjoberg DD; Jibara G; Vickers AJ; Fine S; Eastham J
J Urol; 2021 Apr; 205(4):1063-1068. PubMed ID: 33216696
[TBL] [Abstract][Full Text] [Related]
10. Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer.
Rayn KN; Bloom JB; Gold SA; Hale GR; Baiocco JA; Mehralivand S; Czarniecki M; Sabarwal VK; Valera V; Wood BJ; Merino MJ; Choyke P; Turkbey B; Pinto PA
J Urol; 2018 Nov; 200(5):1041-1047. PubMed ID: 29852182
[TBL] [Abstract][Full Text] [Related]
11. A Multicenter Study of the Clinical Utility of Nontargeted Systematic Transperineal Prostate Biopsies in Patients Undergoing Pre-Biopsy Multiparametric Magnetic Resonance Imaging.
Connor MJ; Eldred-Evans D; van Son M; Hosking-Jervis F; Bertoncelli Tanaka M; Reddy D; Bass EJ; Powell L; Ahmad S; Pegers E; Joshi S; Sri D; Wong K; Tam H; Hrouda D; Qazi H; Gordon S; Winkler M; Ahmed HU
J Urol; 2020 Dec; 204(6):1195-1201. PubMed ID: 32516029
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis.
Goldberg H; Ahmad AE; Chandrasekar T; Klotz L; Emberton M; Haider MA; Taneja SS; Arora K; Fleshner N; Finelli A; Perlis N; Tyson MD; Klaassen Z; Wallis CJD
J Urol; 2020 Jun; 203(6):1085-1093. PubMed ID: 31609177
[TBL] [Abstract][Full Text] [Related]
13. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
15. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
[TBL] [Abstract][Full Text] [Related]
16. Risk of Prostate Cancer after a Negative Magnetic Resonance Imaging Guided Biopsy.
Kinnaird A; Sharma V; Chuang R; Priester A; Tran E; Barsa DE; Delfin M; Kwan L; Sisk A; Felker E; Marks LS
J Urol; 2020 Dec; 204(6):1180-1186. PubMed ID: 32614257
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
18. Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy.
Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Tian Z; Karakiewicz PI; Tilki D; Fisch M; Maurer T; Graefen M; Budäus L
J Urol; 2020 Feb; 203(2):299-303. PubMed ID: 31483694
[TBL] [Abstract][Full Text] [Related]
19. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
20. Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer.
Kinnaird A; Yerram NK; O'Connor L; Brisbane W; Sharma V; Chuang R; Jayadevan R; Ahdoot M; Daneshvar M; Priester A; Delfin M; Tran E; Barsa DE; Sisk A; Reiter RE; Felker E; Raman S; Kwan L; Choyke PL; Merino MJ; Wood BJ; Turkbey B; Pinto PA; Marks LS
J Urol; 2022 Apr; 207(4):823-831. PubMed ID: 34854746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
